<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718887</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-171</org_study_id>
    <nct_id>NCT00718887</nct_id>
  </id_info>
  <brief_title>Suboptimal Responders to Adefovir Switching to Entecavir</brief_title>
  <official_title>A Comparative Study of the Week 12 Antiviral Efficacy and Safety of Switching to Entecavir vs. Continuing Adefovir Treatment in Adults With Chronic Hepatitis B and Suboptimal Response to Adefovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Switching to Entecavir will result in superior antiviral efficacy as compared to continuing
      with Adefovir in patients with a suboptimal response to Adefovir
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level &lt;50 IU/mL at Week 12 by Polymerase Chain Reaction Testing</measure>
    <time_frame>At Week 12 from Day 1</time_frame>
    <description>HBV DNA Level &lt;50 IU/mL=approximately 300 copies/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an HBV DNA Level &lt;50 IU/mL at Week 48 by Polymerase Chain Reaction Testing</measure>
    <time_frame>At Week 48 from Day 1</time_frame>
    <description>HBV=hepatitis B virus. HBV DNA Level &lt;50 IU/mL=approximately 300 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing</measure>
    <time_frame>At Weeks 12 and 48 from Day 1</time_frame>
    <description>HBV=hepatitis B virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)</measure>
    <time_frame>At Weeks 12 and 48 from Day 1</time_frame>
    <description>ULN=upper limit of normal. ALT normalization= ≤1*ULN, among participants with baseline ALT &gt;1*ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion</measure>
    <time_frame>At Weeks 12 and 48 from Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion</measure>
    <time_frame>At Weeks 12 and 48 from Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Genotypic Resistance to Entecavir</measure>
    <time_frame>At Week 48 from Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events, Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, Death as Outcome, Discontinuations Due to AEs, and Abnormalities in Laboratory Test Results (LTR) Leading to Discontinuation</measure>
    <time_frame>Continually from Day 1 through Week 48, and through 24-week follow-up period</time_frame>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results</measure>
    <time_frame>Day 1 through Week 48</time_frame>
    <description>Hematology testing assessed levels of hemoglobin, white blood cells, platelets, neutrophils, international normalized ration, red blood cells, lymphocytes, and monocytes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Entecavir, 0.5 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks</description>
    <arm_group_label>Entecavir, 0.5 mg QD</arm_group_label>
    <other_name>Baraclude</other_name>
    <other_name>BMS-200475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir/Entecavir</intervention_name>
    <description>Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks</description>
    <arm_group_label>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</arm_group_label>
    <other_name>Baraclude</other_name>
    <other_name>BMS-200475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic infection with hepatitis B virus (HBV)(detectable hepatitis B surface antibody
             (HBsAg) at screening and at least 24 weeks prior to screening, or detectable HBsAg for
             &lt;24 weeks and negative for immunoglobulin M core antibody)

          -  Documentation of hepatitis B e antigen (HBeAg) positive or negative status

          -  Naive to nucleoside/nucleotide analogues, with the exception of adefovir

          -  Suboptimal response to adefovir treatment

          -  No lamivudine/telbivudine, entecavir, or adefovir resistance-associated substitutions
             at screening

          -  Male or female gender, aged 16 years and older

          -  Compensated liver function

          -  Serum alanine aminotransferase level &lt;10*upper limit of normal at screening

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Evidence of decompensated cirrhosis

          -  Coinfection with HIV, hepatitis C virus, or hepatitis D virus

          -  Recent history of pancreatitis (within 24 weeks prior to the first dose of study
             medication)

          -  Chronic renal insufficiency, defined as a creatinine clearance &lt;50 mL/min

          -  Current abuse of illegal drugs or alcohol, sufficient in the investigator's opinion to
             prevent adequate compliance with study therapy or to increase the risk of
             hepatotoxicity or pancreatitis

          -  Other serious medical conditions that might preclude completion of this study or that
             require chronic administration of prohibited medications

          -  Serum creatinine level &gt;1.5 mg/dL; hemoglobin level &lt;10.0 g/dL; platelet count
             &lt;70,000/mm^3; absolute neutrophil count &lt;1500 cells/mm^3; serum alpha fetoprotein
             level &gt;100 ng/mL

          -  Except adefovir, any prior therapy with nucleoside or nucleotide analogue antiviral
             agents with activity against hepatitis B (eg, lamivudine, entecavir), or any other
             experimental anti-HBV antiviral, or any China Traditional Medicine

          -  Therapy with interferon, thymosin alpha, or other immunostimulators within 24 weeks of
             randomization

          -  Required chronic administration of medications that cause immunosuppression, that are
             associated with a high risk of nephrotoxicity or hepatotoxicity, or that affect renal
             excretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200235</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <results_first_submitted>October 17, 2012</results_first_submitted>
  <results_first_submitted_qc>January 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 228 participants were enrolled, of which 169 were randomized. A total of 166 participants received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Entecavir, 0.5 mg QD</title>
          <description>Participants with a pervious suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</title>
          <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89">Participants who received treatment.</participants>
                <participants group_id="P2" count="77">Participants who received treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84">Continued in study after 48 weeks</participants>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not identified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entecavir, 0.5 mg QD</title>
          <description>Participants with a pervious suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</title>
          <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="89"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.6" lower_limit="16.9" upper_limit="62.4"/>
                    <measurement group_id="B2" value="34.1" lower_limit="18.9" upper_limit="63.1"/>
                    <measurement group_id="B3" value="33.4" lower_limit="16.9" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level &lt;50 IU/mL at Week 12 by Polymerase Chain Reaction Testing</title>
        <description>HBV DNA Level &lt;50 IU/mL=approximately 300 copies/mL.</description>
        <time_frame>At Week 12 from Day 1</time_frame>
        <population>Participants who were randomized and received at least
1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD) for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Adefovir, 10 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level &lt;50 IU/mL at Week 12 by Polymerase Chain Reaction Testing</title>
          <description>HBV DNA Level &lt;50 IU/mL=approximately 300 copies/mL.</description>
          <population>Participants who were randomized and received at least
1 dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an HBV DNA Level &lt;50 IU/mL at Week 48 by Polymerase Chain Reaction Testing</title>
        <description>HBV=hepatitis B virus. HBV DNA Level &lt;50 IU/mL=approximately 300 copies/mL.</description>
        <time_frame>At Week 48 from Day 1</time_frame>
        <population>Participants who were randomized and received at least
1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an HBV DNA Level &lt;50 IU/mL at Week 48 by Polymerase Chain Reaction Testing</title>
          <description>HBV=hepatitis B virus. HBV DNA Level &lt;50 IU/mL=approximately 300 copies/mL.</description>
          <population>Participants who were randomized and received at least
1 dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                    <measurement group_id="O2" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing</title>
        <description>HBV=hepatitis B virus</description>
        <time_frame>At Weeks 12 and 48 from Day 1</time_frame>
        <population>Participants who were randomized and received at least
1 dose of study drug. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing</title>
          <description>HBV=hepatitis B virus</description>
          <population>Participants who were randomized and received at least
1 dose of study drug. n=number of evaluable participants.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=88, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.2"/>
                    <measurement group_id="O2" value="-0.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=87, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="1.5"/>
                    <measurement group_id="O2" value="-3.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)</title>
        <description>ULN=upper limit of normal. ALT normalization= ≤1*ULN, among participants with baseline ALT &gt;1*ULN</description>
        <time_frame>At Weeks 12 and 48 from Day 1</time_frame>
        <population>Participants who were randomized, who received at least 1 dose of study drug, and whose ALT values were &gt;1*ULN at baseline. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Adeforvi, 10 mg QD/Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)</title>
          <description>ULN=upper limit of normal. ALT normalization= ≤1*ULN, among participants with baseline ALT &gt;1*ULN</description>
          <population>Participants who were randomized, who received at least 1 dose of study drug, and whose ALT values were &gt;1*ULN at baseline. n=number of evaluable participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=51, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4"/>
                    <measurement group_id="O2" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=51, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8"/>
                    <measurement group_id="O2" value="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion</title>
        <time_frame>At Weeks 12 and 48 from Day 1</time_frame>
        <population>Participants who were randomized, who received at least 1 dose of study drug, and who were HBeAg-positive at baseline. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir, 0.5 mg QD</title>
            <description>Participants with a pervious suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Adefovir, 10 mg QD/Entecavir, 10 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion</title>
          <population>Participants who were randomized, who received at least 1 dose of study drug, and who were HBeAg-positive at baseline. n=number of evaluable participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBeAG loss Week 12 (n=79, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAG loss Week 48 (n=79, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBe seroconversion Week 12 (n=79, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBe seroconversion Week 48 (n=79, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion</title>
        <time_frame>At Weeks 12 and 48 from Day 1</time_frame>
        <population>Participants who were randomized and received at least
1 dose of study drug. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion</title>
          <population>Participants who were randomized and received at least
1 dose of study drug. n=number of evaluable participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 HBsAg loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 HBsAg loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 HBsAg seroconversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 HBsAg seroconversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Genotypic Resistance to Entecavir</title>
        <time_frame>At Week 48 from Day 1</time_frame>
        <population>Participants who were randomized and received at least
1 dose of study drug. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Genotypic Resistance to Entecavir</title>
          <population>Participants who were randomized and received at least
1 dose of study drug. n=number of evaluable participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events, Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, Death as Outcome, Discontinuations Due to AEs, and Abnormalities in Laboratory Test Results (LTR) Leading to Discontinuation</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study drug.</description>
        <time_frame>Continually from Day 1 through Week 48, and through 24-week follow-up period</time_frame>
        <population>Participants who were randomized and received at least
1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events, Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, Death as Outcome, Discontinuations Due to AEs, and Abnormalities in Laboratory Test Results (LTR) Leading to Discontinuation</title>
          <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study drug.</description>
          <population>Participants who were randomized and received at least
1 dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormalities in LTR leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results</title>
        <description>Hematology testing assessed levels of hemoglobin, white blood cells, platelets, neutrophils, international normalized ration, red blood cells, lymphocytes, and monocytes.</description>
        <time_frame>Day 1 through Week 48</time_frame>
        <population>Participants who were randomized and received at least
1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir, 0.5 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Adefovir, 10 mg QD</title>
            <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results</title>
          <description>Hematology testing assessed levels of hemoglobin, white blood cells, platelets, neutrophils, international normalized ration, red blood cells, lymphocytes, and monocytes.</description>
          <population>Participants who were randomized and received at least
1 dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Entecavir, 0.5 mg QD</title>
          <description>Participants with a previous suboptimal response to adefovir received entecavir, 0.5 mg once daily (QD), for a maximum of 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Adefovir, 10 mg QD/Entecavir, 0.5 mg QD</title>
          <description>Participants with a previous suboptimal response to adefovir received adefovir, 10 mg QD, for 12 weeks. At 12 weeks, participants were switched to entecavir, 0.5 mg QD, for a maximum of 40 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

